Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.53 |
| ▸ | APLNR | P35414 | 1/20 | 0.53 |
| ▸ | CCR6 | P51684 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30182411 | 1.00 | RAB9A (0.53) | RAB9AKMT2AHSP90AA1CXCR5APLNR | |
| Ammonia Solution, Strong SCHEMBL27646035 | 0.98 | RAB9A (0.51) | RAB9AKMT2AHSP90AA1CXCR5APLNR | |
| SCHEMBL16835964 | 0.88 | MAPT (0.47) | RAB9AKMT2AHSP90AA1CXCR5APLNR | |
| SCHEMBL177869 | 0.80 | HTT (0.58) | RAB9AKMT2AACHEHSD17B10ALDH1A1 | |
| SCHEMBL15690970 | 0.80 | KMT2A (0.55) | RAB9AKMT2AHSP90AA1CXCR5APLNR | |
| SCHEMBL26005944 | 0.80 | POLB (0.57) | RAB9AKMT2AACHEHSD17B10ALDH1A1 | |
| SCHEMBL3156019 | 0.77 | MAPT (0.52) | RAB9AKMT2AHSP90AA1CXCR5APLNR | |
| SCHEMBL31683275 | 0.76 | SIRT6 (0.62) | KMT2AALDH1A1MAPTMEN1SMN1; SMN2 | |
| SCHEMBL4892045 | 0.76 | MAPT (0.50) | RAB9AKMT2AHSP90AA1CXCR5APLNR | |
| SCHEMBL10936934 | 0.76 | MAPT (0.50) | RAB9AKMT2AHSP90AA1CXCR5APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12442027-B2 | Method of reducing aromatic nitro compounds | AMGEN INC. (US) | 2025-10-14 | — | — | US | claimed |
| US-12269811-B2 | Synthesis of omecamtiv mecarbil | AMGEN INC. (US) | 2025-04-08 | — | — | US | claimed |
| EP-4305018-A2 | SYNTHESIS OF OMECAMTIV MECARBIL | Amgen Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| CN-117157274-A | Synthesis of olmesartan Mo Kabi mol | 安进股份有限公司 | 2023-12-01 | — | — | CN | claimed |
| US-20230373955-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC. | 2023-11-23 | — | — | US | claimed |
| EP-4265597-A2 | SYNTHESIS OF OMECAMTIV MECARBIL | Amgen Inc. (US) | 2023-10-25 | — | — | EP | claimed |
| US-11753394-B2 | Synthesis of omecamtiv mecarbil | AMGEN INC. (US) | 2023-09-12 | — | — | US | claimed |
| EP-3925950-B1 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC (US) | 2023-09-06 | — | — | EP | claimed |
| US-11702380-B2 | Synthesis of omecamtiv mecarbil | AMGEN INC. (US) | 2023-07-18 | — | — | US | claimed |
| CN-110799503-B | Synthesis of Meicartine | 美国安进公司 | 2023-06-27 | — | — | CN | claimed |
| WO-2022192414-A2 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC. (US) | 2022-09-15 | — | — | WO | claimed |
| EP-3925950-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | Amgen Inc. (US) | 2021-12-22 | — | — | EP | claimed |
| US-20210371397-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN, INC. | 2021-12-02 | — | — | US | claimed |
| US-20200308143-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC. | 2020-10-01 | — | — | US | claimed |
| WO-2020131574-A1 | METHOD OF REDUCING AROMATIC NITRO COMPOUNDS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | claimed |
| EP-3645518-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | Amgen Inc. (US) | 2020-05-06 | — | — | EP | claimed |
| CN-110799503-A | Synthesis of mecamitocainide | 美国安进公司 | 2020-02-14 | — | — | CN | claimed |
| WO-2019006231-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | AMGEN INC. (US) | 2019-01-03 | — | — | WO | claimed |
| CN-101560183-B | Method for preparing 5-bromo-2-methylpyridine | ZHEJIANG MED XINCHANG PHARM | 2011-02-02 | — | — | CN | claimed |
| CN-101560183-A | Method for preparing 5-bromo-2-methylpyridine | ZHEJIANG MEDICINE CO LTD (CN) | 2009-10-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12442027-B2 | Method of reducing aromatic nitro compounds | NNMT, CBR3, DHFR | RAB9A 4441/4885KMT2A 718/4885HSP90AA1 1612/4885 |
| US-20200308143-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | SI, DPYD, MTHFD2 | RAB9A 4038/4885KMT2A 611/4885HSP90AA1 1221/4885 |
| US-11702380-B2 | Synthesis of omecamtiv mecarbil | SI, MTHFD2, DPYD | RAB9A 4193/4885KMT2A 563/4885HSP90AA1 1515/4885 |
| US-20230373955-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | DPYD, SI, MTHFD2 | RAB9A 4033/4885KMT2A 591/4885HSP90AA1 1188/4885 |
| US-12269811-B2 | Synthesis of omecamtiv mecarbil | DPYD, SI, MTHFD2 | RAB9A 4033/4885KMT2A 591/4885HSP90AA1 1188/4885 |
| US-11753394-B2 | Synthesis of omecamtiv mecarbil | SI, DPYD, MTHFD2 | RAB9A 4024/4885KMT2A 549/4885HSP90AA1 1412/4885 |
| US-20210371397-A1 | SYNTHESIS OF OMECAMTIV MECARBIL | SI, DPYD, MTHFD2 | RAB9A 4024/4885KMT2A 549/4885HSP90AA1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.